Innovative research sheds light on migraine mechanisms and potential therapies

FHS
July 5, 2024
2:19 am

New research describes for the first time how a spreading wave of disruption and the flow of fluid in the brain triggers headaches, detailing the connection between the neurological symptoms associated with aura and the migraine that follows.

RP-3 by Replimune for Melanoma: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Melanoma.

November 18, 2023

Study reveals trigonelline as a therapeutic agent for mitochondrial dysfunction in aging

Sarcopenia is the age-related decline in skeletal muscle due to the wasting of myofiber.

March 26, 2024

FDA grants priority review to AstraZeneca’s Imfinzi sBLA for MIBC

AstraZeneca’s sBLA submission is supported by outcomes from a multi-centre Phase III trial. Credit: © AstraZeneca 2024. The US Food and Drug Administration (FDA) has

December 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.